Revised risk model for inspections may include country of origin
This article was originally published in The Gold Sheet
Executive Summary
FDA may be revising its risk ranking model to include adding the country of origin as a factor in deciding which firms to inspect first, reported Edwin Rivera-Martinez, CDER branch chief for manufacturing assessment and pre-approval compliance, at the recent GMP by the Sea Conference in Cambridge, Md. The agency totals up a risk score in three areas to determine the firm's chances for being inspected: the facility score, the product score, and the process score. The higher the total score, the greater the chances the site will be chosen for inspection. FDA uses the model to prioritize its routine surveillance inspection program for domestic and foreign sites in light of the dramatic decline in agency resources available for inspections in recent years. "This model is still evolving and drives about half of our inspections," he said. "One of the things we are considering as another risk factor is whether or not we should have a risk category for a country where we know from our experience that we have, say, an underdeveloped regulatory body and perhaps we should incorporate this risk factor into our model," reported Rivera. The facility score looks at the size of the facility, the type of establishment such as whether the firm is a drug manufacturer or a contract sterilizer, the results of the last three inspections, and the firm's field alert history. The product score looks at whether the drug is a prescription drug or an OTC drug, the drug's therapeutic category, and whether the drug is sterile or non-sterile. The process score evaluates the ability of the firm to maintain the manufacturing process in the state of control and the potential for contamination
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.